LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results GlobeNewswire May 20, 2021 IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) LAVA Therapeutics.
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
May 20, 2021 08:00 ET | Source: Replimune Group Inc Replimune Group Inc Woburn, Massachusetts, UNITED STATES
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma
Dosed first patient with RP1 in the anti-PD1 failed NSCLC lung cancer cohort of the IGNYTE study
Data update on lead programs to be provided during virtual investor event on June 3, 2021
Strengthened management team to prepare for potential commercial launch and enable further later stage development
E-Mail
IMAGE: HPV infection causes cells to undergo changes. If not treated these cells can, over time, become cancer cells. view more
Credit: National Cancer Institute
Today, doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation s health care systems, physicians, parents and children, and young adults to get the human papillomavirus (HPV) vaccination back on track.
Dramatic drops in annual well visits and immunizations during the COVID-19 pandemic have caused a significant vaccination gap and lag in vital preventive services among U.S. children and adolescents especially for the HPV vaccine. The pandemic also has exacerbated health disparities, leaving Black, Indigenous and other people of color; rural; and sexual minority adolescents at even greater risk for missed doses of this cancer prevention vaccine.
LAVA Therapeutics BV: LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
Clinical development plans on schedule in both hematological and solid tumor programs
Leadership strengthened through key management and board appointments
UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in gamma-delta bispecific T cell engagers (bsTCEs) to transform cancer therapy, today reported its business update and first quarter 2021 financial results. We continue to make important strides across all aspects of our business as we transition to a clinical stage organization, said Stephen Hurly, chief executive officer of LAVA Therapeutics. With the recent additions to our leadership team and board and the proceeds from our IPO, we are well-positioned to advance our pipeline as we work toward our mission of transforming cancer therapy for patie
Rain Therapeutics Appoints Robert Doebele, M D , Ph D as President Dr Doebele, Rain co-founder, will continue to serve as chief scientific officer biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.